{"id":"W3203793933","doi":"10.1016/j.annonc.2021.08.1040","title":"518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Sierra Oncology; PharmaMar; Eisai; G1 Therapeutics; MacroGenics; Silverback Therapeutics; Astex Pharmaceuticals; Ribon Therapeutics; Syndax Pharmaceuticals; Pfizer; Innovent Biologics; Incyte; NuCana; Daiichi Sankyo Europe; Calithera Biosciences; Mersana Therapeutics; Amgen; Radius Health; Deciphera Pharmaceuticals; Jounce Therapeutics; Ipsen; Five Prime Therapeutics; Merck KGaA; Puma Biotechnology; Regeneron Pharmaceuticals; Plexxikon; Seagen; Relay Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Tolerability; Solid tumor; Pharmacology; Oncology; Internal medicine; Adverse effect; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003138309,0.0003556662,0.0006806724,0.0001239117,0.0002186741,0.0002827359,0.0001695042,0.0002798086,0.002922755],"category_scores_gemma":[0.0004567903,0.0001566643,0.0004871394,0.0001453304,0.0002011971,0.0002507255,0.000108821,0.0009935271,0.0005324503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003002626,"about_ca_system_score_gemma":0.0003349338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189057,"about_ca_topic_score_gemma":0.00305025,"domain_scores_codex":[0.9998903,0.00003658588,0.000007366651,0.00001732571,0.00001672901,0.00003168311],"domain_scores_gemma":[0.9998241,0.00005941481,0.00002934102,0.00001559313,0.0000199919,0.00005152723],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1747658,0.007208348,0.03437326,0.0008392136,0.0007370982,0.001602091,0.000353796,0.005046382,0.4324743,0.0004562516,0.007082026,0.3350615],"study_design_scores_gemma":[0.02865501,0.3631575,0.4454987,0.0001296628,0.001701948,0.0063919,0.0003393345,0.007024433,0.1103761,0.0005245878,0.03609612,0.0001046883],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885616,0.00380938,0.0005984597,0.0003964076,0.00006655891,0.0001497888,0.001047986,0.00007661555,0.005293185],"genre_scores_gemma":[0.9948152,0.001021188,0.0002671758,0.0001623426,0.00005087272,0.0000421703,0.00122963,0.00002172108,0.002389635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002922755,"threshold_uncertainty_score":0.009777546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03554816202193303,"score_gpt":0.3668076639738672,"score_spread":0.3312595019519342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}